Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Beta-Thalassemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Beta-Thalassemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Beta-Thalassemia is an inherited blood disorder characterized by decreased levels of functional hemoglobin, which is the iron containing protein present in red blood cells that carries oxygen to the cells throughout the body. People with Beta-Thalassemia will be suffering from lack of oxygen supply in body and also shortage of red blood cells and will be at the increased risk of developing abnormal blood clots.

Symptoms of Beta-Thalassemia includes pale skin, jaundice, enlarged spleen, liver and heart, delayed puberty. Beta-Thalassemia can be diagnosed by molecular and genetic tests, blood tests etc. Treatment of Beta-Thalassemia includes frequent blood transfusions, bone marrow transplant, surgery to remove spleen or gallbladder and medications.

 

Segmentation:

By Trial Phase, Beta-Thalassemiapipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Beta-Thalassemiapipeline drugs are segmented as:

  • Celgene Pharmaceuticals
  • bluebird bio.Inc
  • GlaxoSmithKline
  • Acceleron Pharma, Inc.
  • Sanofi
  • Novartis
  • HemaQuest Pharmaceuticals Inc.
  • Hoffmann-La Roche
  • FerroKinBioSciences, Inc.
  • Others

By Drugs, Beta-Thalassemia pipeline drugs are segmented as:

  • LentiGlobin
  • Deferitrin
  • Desferoxamine
  • Bitopertin
  • Deferasirox
  • Luspatercept
  • Zoledronic acid
  • Ambrisentan
  • Others

By Type of Condition, Beta-Thalassemia pipeline drugs are segmented as:

  • Thalassemia Major (Cooley’s anemia)
  • Thalassemia Intermedia

By Route of Administration, Beta-Thalassemiapipeline drugs are segmented as:

  • Oral
  • Parenteral

 

Space Analysis:

  • In October 2017, Sangamo Therapeutics and Bioverativreceived U.S.FDA IND acceptance to begin human clinical studies of ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia.
  • In September 2016, bluebird bio, Inc. commenced a phase III global multi center study of its HGB-207  in patients with transfusion-dependent beta-thalassemia with non-β00genotypes
  • In May 2015, Luspatercept of Celgene Corporation and Acceleron Pharma Inc. was granted Fast track designations by U.S. FDA for two separate indications, for the treatment of patients with transfusion dependent beta-thalassemia and patients with non-transfusion dependent beta-thalassemia. Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members of the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation

 

Report Description:

Beta-ThalassemiaDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Beta-Thalassemia treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Beta-Thalassemia disease pipeline drugs development. This report studies the dynamics of the Beta-Thalassemia Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Beta-Thalassemia disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases
  1. Table of Content
  2. Executive Summary
  3. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Introduction
    • Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market – Taxonomy
    • Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market –Definitions
      • Trial Phase
      • Drugs
      • Type of Condition
      • Route of Administration
  1. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamic Factors – Impact Analysis
    • Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market – Competition Landscape
    • Epidemiology
  2. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market, By Trial Phase, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Preclinical Trials
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 1
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 2
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 3
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 4
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Forecast, By Drugs,2013 – 2017 and Forecast, 2018 – 2024
    • LentiGlobin
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Deferitrin
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Desferoxamine
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Bitopertin
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Deferasirox
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Luspatercept
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Zoledronic acid
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Ambrisentan
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Forecast, By Type of Condition, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Thalassemia Major (Cooley’s anemia)
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Thalassemia Intermedia
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Oral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Region, 2018 – 2024
  2. North America Beta-Thalassemia Disease Pipeline Drugs Assessment MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • LentiGlobin
      • Deferitrin
      • Desferoxamine
      • Bitopertin
      • Deferasirox
      • Luspatercept
      • Zoledronic acid
      • Ambrisentan
      • Others
    • Type of Condition Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Thalassemia Major (Cooley’s anemia)
      • Thalassemia Intermedia
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Beta-Thalassemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Country, 2018 – 2024
    • North America Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics – Trends
  3. Europe Beta-Thalassemia Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • LentiGlobin
      • Deferitrin
      • Desferoxamine
      • Bitopertin
      • Deferasirox
      • Luspatercept
      • Zoledronic acid
      • Ambrisentan
      • Others
    • Type of Condition Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Thalassemia Major (Cooley’s anemia)
      • Thalassemia Intermedia
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Beta-Thalassemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Country, 2018 – 2024
    • Europe Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics – Trends
  4. Asia-Pacific Beta-Thalassemia Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • LentiGlobin
      • Deferitrin
      • Desferoxamine
      • Bitopertin
      • Deferasirox
      • Luspatercept
      • Zoledronic acid
      • Ambrisentan
      • Others
    • Type of Condition Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Thalassemia Major (Cooley’s anemia)
      • Thalassemia Intermedia
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Beta-Thalassemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Country, 2018 – 2024
    • Asia-Pacific Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics – Trends
  5. Latin America Beta-Thalassemia Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • LentiGlobin
      • Deferitrin
      • Desferoxamine
      • Bitopertin
      • Deferasirox
      • Luspatercept
      • Zoledronic acid
      • Ambrisentan
      • Others
    • Type of Condition Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Thalassemia Major (Cooley’s anemia)
      • Thalassemia Intermedia
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Beta-Thalassemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Country, 2018 – 2024
    • Latin America Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics – Trends
  6. Middle East and Africa Beta-Thalassemia Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • LentiGlobin
      • Deferitrin
      • Desferoxamine
      • Bitopertin
      • Deferasirox
      • Luspatercept
      • Zoledronic acid
      • Ambrisentan
      • Others
    • Type of Condition Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Thalassemia Major (Cooley’s anemia)
      • Thalassemia Intermedia
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Beta-Thalassemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Country, 2018 – 2024
    • MEA Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Trial Phase& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Celgene Pharmaceuticals
      • bluebird bio.Inc
      • GlaxoSmithKline
      • Acceleron Pharma, Inc.
      • Sanofi
      • Novartis
      • HemaQuest Pharmaceuticals Inc.
      • Hoffmann-La Roche
      • FerroKinBioSciences, Inc.
  1. Research Methodology
  2. Key Assumptions and Acronyms

 

  1. Disclaimer
  2. The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553